Table 1 MSK Model Information Sheet questions (2024 version)
From: Responsible Artificial Intelligence governance in oncology
Category | Requested Information |
---|---|
General | MSK Business Sponsor |
MSK Business Lead | |
Strategic Alignment Category | |
Impacted Users | |
Primary Function/Objective | |
Expected Benefits (Use/Impact metrics) | |
Development Team | |
Development Staff Members | |
Link(s) to model documentation | |
Key words (tags for search within Registry) | |
Is this an externally acquired solution (vendor)? | |
Technical | System of Use/Record (i.e., where users will experience it) |
Data Sources Used | |
Does it have PHI? | |
Does it have PII? | |
Is it subject to GDPR? | |
Model Training Methods/Model Type | |
Model Performance Metrics | |
Development Platform | |
Github Link to code | |
IRB link (if applicable) | |
Fairness Assessment Method | |
FDA SaMD Screening | Info Type: Communicable in normal clinical conversation? |
Output: Gives clinician directive or recommendation? | |
Disclosure to Clinician: Gives basis for recommendation? Dynamic or “learning” algorithm? | |
FDA SaMD Determination | |
Other Regulatory Determination TBD (e.g., State regs, ONC, NIST, etc.) | |
Approval Status | Silent Pilot Approval |
Full Production Launch Approval | |
Anticipatable AI-induced Adverse Events (aiAE’s) | |
How often is performance re-evaluation required? | |
Last post-launch date/status of review of relevant research and evidence |